Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2011

Epistem to Evaluate Xcelris' Genedrive PoC System for TB Diagnosis in India

  • U.K.-firm Epistem and Indian genomics research and diagnostics testing specialist Xcelris Laboratories are teaming up to evaluate the use of Epistem’s Genedrive™ point-of-care molecular diagnostic device in India’s Revised National Tuberculosis Control Programme (RNTCP), which was initiated in 1997 to aid in the rapid diagnosis and treatment of TB throughout the country.

    The Genedrive system has been developed to provide rapid, low-cost  analysis of molecular biomarkers in a simple, integrated unit, with results generated in less than 30 minutes. Through the collaboration with Xcelris the handheld device will be evaluated for the early identification of TB infection. After the evaluation stage the partners anticipate rolling out the device into select remote locations prior to a full evaluation of market positioning.

    Xcelris offers genomics and bioinformatics services to research institutes in India and globally, and has expertise in next-generation sequencing and novel molecular diagnostic techniques. The firm will partner with the RNTCP on the provision of easy-to-use diagnostic solutions to aid in TB prevention and therapy in India.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »